RecruitingPhase 4NCT06777758

Comparison of Remimazolam and Propofol in Endoscopic Examinations and Treatments

The Comparison of Remimazolam or Propofol Used Alone Versus in Combination for Moderate Sedation During Endoscopic Examination and Treatment.


Sponsor

Kaohsiung Veterans General Hospital.

Enrollment

90 participants

Start Date

Feb 12, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

This study aims to evaluate the efficacy and safety of Remimazolam, either used alone or in combination with Propofol, for moderate sedation anesthesia during endoscopic therapies or examinations. Additionally, it seeks to explore whether their combination can further enhance the quality of patient anesthesia and recovery outcomes.


Eligibility

Min Age: 20 YearsMax Age: 80 Years

Inclusion Criteria3

  • Subjects are between 20-80 years old.
  • Anesthesiologists rated ASA as between I and III.
  • Patients undergoing upper gastrointestinal endoscopic examination or therapy.

Exclusion Criteria7

  • Allergy to Propofol, Remimazolam, or opioid medications.
  • Emergency surgery.
  • Pregnancy.
  • History of malignant hyperthermia.
  • Impaired liver or kidney function.
  • Airway difficulties due to pharyngeal tumors.
  • Refusal to participate.

Interventions

DRUGRemimazolam

Remimazolam

DRUGPropofol

Propofol dose reduction ratio


Locations(1)

Kaohsiung Veterans General Hospital

Kaohsiung City, Taiwan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06777758


Related Trials